Prevention of influenza and acute respiratory viral infections during the period of seasonal rise in morbidity

Cite item

Full Text


In the article, the author provides data on the features of the course of the new COVID-19 infection and its relationship with the course of various acute respiratory viral infections (ARVI). Emphasis is placed on the need for timely prevention of ARVI in connection with the proven fact that a previous illness with influenza or ARVI can significantly increase the risk of developing COVID-19. It has been shown that at present, specific prophylaxis is carried out only for influenza, while it does not always allow achieving good results, and in relation to other viruses (adenoviruses, parainfluenza viruses, rhinoviruses, etc.) it is not carried out at all. In this regard, it is of particular importance to carry out the so-called non-specific prophylaxis. As the latter, it is proposed to use homeopathic medicines with proven efficacy. One of them is Oscillococcinum. The data of experimental and clinical justification (randomized placebo-controlled trials) of the use of this drug in ARVI prevention programs are presented. Its effectiveness and safety in both adults and children are underlined.

Full Text

Restricted Access

About the authors

Irina N. Kholodova

Russian Medical Academy of Continuous Professional Education

Moscow, Russia


  1. Bruyndonck R, Coenen S, Butler C et al. Respiratory syncytial virus and influenza virus infection in adult primary care patients: Association of age with prevalence, diagnostic features and illness course. Int J Infect Dis 2020; 95: 384-90. doi: 10.1016/j.ijid.2020.04.020
  2. Li Y, Wang J, Wang C et al. Characteristics of respiratory virus infection during the outbreak of 2019 novel coronavirus in Beijing. Int J Infect Dis. 2020; 96: 266-9. doi: 10.1016/j.ijid.2020.05.008
  3. Ipsos Comcon. HealthIndexTM «Исследование конечных потребителей», заболеваемость 2019 г. в Москве. [Ipsos Comcon. HealthIndexTM "Issledovanie konechnykh potrebitelei', zabolevae-most" 2019 g. v Moskve (in Russian).]
  4. Заболеваемость гриппом и ОРВИ в РФ. Информационный бюллетень Роспотребнадзора.
  5. Селькова Е.П., Волчецкий АЛ., Лапицкая А.С. и др. Влияние Оциллококцинума на интерферонобразование у часто болеющих детей. Consilium Medicum. Педиатрия. 2009; 4: 42-7.
  6. ELEMENT_ID=11277. Сведения об инфекционных и паразитарных заболеваниях за 2018 г.
  7. Paget J, Spreeuwenberg P, Charu V et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health 2019; 9 (2): 020421. doi: 10.7189/jogh.09.020421
  8. Zhang L, Zhang Y. Influenza Viral Infection is a High-Risk Factor for Developing Coronavirus Disease 2019 (COVID-19). Preprints 2020, 2020030307. doi: 10.20944/preprints202003.0307.v1
  9. Кареткина Г.Н. Грипп, ОРВИ: проблемы профилактики и лечения. Инфекционные болезни: Новости. Мнения. Обучение. 2015; 4 (13): 25-34.
  10. Marrari LA, Terzan L, Chaufferin G. Oscillococcinum for influenza treatment. Ann Ist Super San На 2012; 48 (1): 105-9. doi: 10.4415/Ann_12_01_17
  11. Beghi GM, Morselli-Labate AM. Does homeopathic medicine have a preventive effect on respiratory tract infections? A real life observational study. Multidisciplinary Respiratory Medicine 2016; 11 (1). doi: 10.1186/s40248-016-0049-0
  12. Коваленко Л.П., Толлерова А.В., Кузнецова О.С. и др. Экспериментальное изучение аллергизирующих свойств и иммунотоксичности препарата Оцилло-кокцинум. Токсикологический вестн. 2015; 1 (130): 37-41.
  13. Casanova P, Gerard R. Bilan de 3 annOes d’Otudes randomisOes multicentriques Oscillococcinum/placebo. Proposta Omeopatica 1988; 6: 14-7.
  14. Ferley JP, Zmirou D, D’Adhemar D et al. A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like syndromes. Br J Clin Pharmacol 1989; 27: 329-35.
  15. Papp R, Schuback G, Beck E et al. Oscillococcinum in patients with influenza-like syndromes: a placebo controlled double-blind evaluation. A controlled trial. Br Homeopath J 1998; 87: 69-76.
  16. Селькова Е.П., Алешина Е.Н., Штундер И.П. и др. Современные препараты в лечении гриппа и ОРВИ. Оциллококцинум. РМЖ. 2008; 16 (22): 1510-4.
  17. Селькова Е.П., Семененко ТА., Горбачев ИА. Применение Оциллококцинума для профилактики и лечения гриппа и ОРВИ. Инфекционные болезни. 2005; 3 (4): 74-8.
  18. Vickers AJ, Smith C. Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndrome (Review). Cochrane Database Syst Rev 2006; 3: CD001957.
  19. Mathie RT, Frye J, Fisher P. Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like illness. Cochrane Database Syst Rev 2012. doi: 10.1002/14651858.cd001957.pub5
  20. Mathie RT, Frye J, Fisher P. Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like illness. Cochrane Database Syst Rev 2015. doi: 10.1002/14651858.cd001957.pub6
  21. Самсыгина Г.А., Богомильский М.Р., Казюкова Т.В. и др. Профилактика и терапия острых респираторных заболеваний с использованием гомеопатических средств. Педиатрия. Журнал им. Г.Н.Сперанского. 2008; 87 (6): 92-6.
  22. Клиническая фармакология и фармакотерапия. Учебник. 3-е изд., доп. и пере-раб. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.
  23. Казюкова ТВ., Панкратов И.В., Алеев А.С., Дудина ТА. Семейная профилактика гриппа и острых респираторных инфекций в период подъема сезонной заболеваемости. РМЖ. 2011; 10 (2): 118-23.
  24. Colombo GL, Di Matteo S, Martinotti C et al. The preventive effect on respiratory tract infections of Oscillococcinum. A cost-effectiveness analysis. ClinicoEconomics Outcomes Res 2018; 10: 75-82. doi: 10.2147/ceor.s14430026

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies